Agios Business Highlights and Second Quarter 2022 Financial Results

 Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND® (mitapivat) Sales –

– Brian Goff to Become Chief Executive Officer at Agios on August 8, 2022, Leveraging 30+ Years of Biopharma Experience, Including Significant Expertise in Rare Disease and Hematology; Current CEO Jackie Fouse to Become Chair of the Board –

– Actively Enrolling Patients in Five PYRUKYND® Pivotal Studies Across Thalassemia, Sickle Cell Disease and Pediatric Pyruvate Kinase (PK) Deficiency –

– $1.1 Billion of Cash, Cash Equivalents and Marketable Securities as of June 30, 2022 –

https://finance.yahoo.com/news/agios-reports-business-highlights-second-110000837.html